Scientific, regulatory, and societal upheavals in the last three years are making early-stage productdevelopment more complex. The COVID-19 pandemic highlighted ethnic and racial disparitiesin clinical research access and health outcomes, prompting regulatory agencies to scrutinize thediversity of patients in clinical trials; precision medicines have expanded beyond oncology andoften demand the simultaneous development of companion diagnostics and massively parallelsequencing to identify
关注微信
